Applying PET/MR for Dementia Applications
キーワード
概要
説明
Simultaneous measurements of PET and MR together as is recently became possible have allow spatial and temporal correlation between the two modalities opening a window of opportunities that was not available so far. The first practical advantage is because most neurological patients should go through both MRI and PET scans. Allowing both scans in the occasion significantly increase patient comfort. Furthermore, the simultaneous scans in contrast to sequential scans allow correlation between PET and MR informaiton without the concern of pathological brain modifications between the scans. Currently PET is performed combined with CT, which is superior to MR in the field of brain images. MR high soft tissue resolution as well as extra information it may provide regarding brain perfusion, diffusion, metabolic parameters etc., make the MR a far better modality for brain imaging than CT. In addition, the combined tool allow leveraging MR data to improve PET data quantification. PET issues such as motion correction, partial volume effect and correct localization of the tracer in the brain anatomy that cause PET image degradation and lower accuracy and robustness of PET quantitative parameters, can be solved by integrating MR data into the analysis. Several recently published articles have demonstrated different correction approaches for motion correction and partial volume effect showing an improvement in the PET images both visually and quantitatively . PET attenuation correction using MR data have also been studied, however this matter still need to be resolved. PET/MR for neurological conditions, in general, and specifically for conditions resulting in dementia, is a promising application with a large variety of research opportunities and its abilities need to be explored. Optimization of the acquisition protocols and even more so, the analysis and quantification protocols still need to be performed and will be the focus of this study.
日付
| 最終確認済み: | 10/31/2019 |
| 最初に提出された: | 10/28/2019 |
| 提出された推定登録数: | 11/03/2019 |
| 最初の投稿: | 11/05/2019 |
| 最終更新が送信されました: | 11/03/2019 |
| 最終更新日: | 11/05/2019 |
| 実際の研究開始日: | 01/09/2020 |
| 一次完了予定日: | 03/09/2021 |
| 研究完了予定日: | 01/09/2022 |
状態または病気
介入/治療
Diagnostic Test: Dementia Patients
段階
アームグループ
| 腕 | 介入/治療 |
|---|---|
| Experimental: Dementia Patients | Diagnostic Test: Dementia Patients The PET will be performed with one of the following tracers: 18F-FDG, 18F-DOPA or 18F-flutemetamol (Vizamyl). Proper tracer will be determined by the physician according to the condition. Patients that will agree, will be asked to perform two scans each with different tracer. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, perfusion and diffusion images. Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Hidden image parameters will also be extracted for texture analysis purposes. Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity. |
適格基準
| 研究の対象となる年齢 | 18 Years に 18 Years |
| 研究に適格な性別 | All |
| 健康なボランティアを受け入れる | はい |
| 基準 | Inclusion Criteria: patients over the age of 18 with diagnosed conditions that might result in dementia or with diagnosed dementia in different stages. Exclusion Criteria: 1. Patients younger than 18 years 2. pregnancy 3. contraindication to MRI or to intravenous gadolinium injection. |
結果
主な結果の測定
1. Patients who preformed PET/MR for dementia applications [1 year]
